Storyline
New preclinical and early clinical studies explore immunotherapy combinations and radiosensitizers in cancer treatment
Recent research highlights advances in cancer therapeutics, including dual targeting of PSGL-1 and BRAF/MEK to delay melanoma relapse, evaluation of CD47 blockade combined with anti-GD2 antibody in neuroblastoma models, and a phase I trial of Selinexor with chemoradiation in glioblastoma.
Published 2026-07-07 22:38 UTCUpdated 2026-07-08 05:21 UTC
Current brief openSource links open
This current storyline is open here with summary, metadata, source links, continuity context, and full evidence. Paid is for compare-over-time, alerts, exports, and workflow.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
Recent research highlights advances in cancer therapeutics, including dual targeting of PSGL-1 and BRAF/MEK to delay melanoma relapse, evaluation of CD47 blockade combined with anti-GD2 antibody in neuroblastoma models, and a phase I trial of Selinexor with chemoradiation in glioblastoma.
Score total
1.16
Momentum 24h
3
Posts
3
Origins
2
Source types
1
Duplicate ratio
0%
Why now
- Resistance to current melanoma therapies necessitates new combination approaches.
- Chemoresistant neuroblastoma remains a clinical challenge requiring novel immunomodulatory treatments.
- Glioblastoma patients urgently need improved radiosensitizing agents to enhance standard care efficacy.
Why it matters
- Combining PSGL-1 blockade with targeted therapy may overcome resistance in melanoma, improving patient outcomes.
- Understanding limitations of CD47 blockade in neuroblastoma guides future immunotherapy strategies.
- Establishing safe dosing of Selinexor with chemoradiation supports development of radiosensitizers for glioblastoma.
Continuity snapshot
- Trend status: insufficient_history.
- Continuity stage: seed.
- Current status: open.
- 3 current source-linked posts are attached to this storyline.
All evidence
All evidence
PSGL-1 blockade delays relapse to BRAF/MEK inhibition in cutaneous melanoma
bioRxiv (all subjects) · biorxiv.org · 2026-07-08 05:21 UTC
Phase I dose escalation of the Exportin 1 inhibitor, Selinexor, in combination with chemoradiation in patients with newly diagnosed glioblastoma
medRxiv (all subjects) · medrxiv.org · 2026-07-07 22:38 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- bioRxiv (all subjects) (1)
- medRxiv (all subjects) (1)
Top origin domains (this list)
- biorxiv.org (1)
- medrxiv.org (1)